Biological and virologic characteristics of primary HIV infection

被引:222
作者
Schacker, TW
Hughes, JP
Shea, T
Coombs, RW
Corey, L
机构
[1] Univ Washington, Dept Lab Med 357110, Seattle, WA 98195 USA
[2] Univ Washington, Seattle, WA 98122 USA
[3] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA
[4] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
关键词
human immunodeficiency virus infections; disease progression; RNA; viral; CD4 lymphocyte count; viral load;
D O I
10.7326/0003-4819-128-8-199804150-00001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The clinical events surrounding acute HIV-1 infection have been well described, but little is known about whether the virologic course of acute HIV-1 infection influences the subsequent progression of disease. Objective: To define the virologic natural history of acute and very early HIV infection. Design: Prospective, longitudinal cohort study. Setting: University of Washington Research Clinic. Participants: 74 adults enrolled soon after acquisition of HIV (mean, 69 days). Measurements: Plasma HIV-1 RNA levels; quantitative cell cultures; CD4 cell counts; and detailed clinical assessments done at study entry, biweekly for 1 month, monthly for 2 months, and quarterly thereafter. Results: In the first 30 days after acquisition of HIV, HIV-1 RNA levels varied greatly among participants (range, 27 200 to 1.6 x 10(6) copies per mt of plasma). Levels of HIV-1 RNA decreased by a mean of 6.5% per week for the first 120 days and then increased by a mean of 0.15% per week. CD4 cell counts decreased by a mean of 5.2 cells/mm(3) per week for the first 160 days and by a mean of 1.9 cells/mm(3) per week thereafter (P < 0.01). Disease progressed faster in participants who sought medical care for their acute seroconversion syndrome (P = 0.01) and those who had high plasma HIV-1 RNA levels 120 to 365 days after acquisition (P < 0.01). Peak levels in the first 120 days were not predictive of disease progression. Conclusions: The variability in viral RNA levels associated with acute HIV-1 infection is greater than previously appreciated. Within 120 days of acquisition, plasma HIV RNA levels rapidly decrease to an inflection point, after which they gradually increase. Virus-host interactions soon after acquisition seem to have a major influence on the long-term outcome of HIV-1 disease.
引用
收藏
页码:613 / +
页数:9
相关论文
共 40 条
  • [1] ACUTE PRIMARY HIV-ESOPHAGITIS
    BARTELSMAN, JFWM
    LANGE, JMA
    VANLEEUWEN, R
    VANDENTWEEL, JG
    TYTGAT, GNJ
    [J]. ENDOSCOPY, 1990, 22 (04) : 184 - 185
  • [2] HIGH TITERS OF CYTOPATHIC VIRUS IN PLASMA OF PATIENTS WITH SYMPTOMATIC PRIMARY HIV-1 INFECTION
    CLARK, SJ
    SAAG, MS
    DECKER, WD
    CAMPBELLHILL, S
    ROBERSON, JL
    VELDKAMP, PJ
    KAPPES, JC
    HAHN, BH
    SHAW, GM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (14) : 954 - 960
  • [3] Cleveland W. S., 1992, STAT MODELS S PACIFI
  • [4] Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine
    Collier, AC
    Coombs, RW
    Schoenfeld, DA
    Bassett, RL
    Timpone, J
    Baruch, A
    Jones, M
    Facey, K
    Whitacre, C
    McAuliffe, VJ
    Friedman, HM
    Merigan, TC
    Reichman, RC
    Hooper, C
    Corey, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (16) : 1011 - 1017
  • [5] PLASMA VIREMIA IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTION
    COOMBS, RW
    COLLIER, AC
    ALLAIN, JP
    NIKORA, B
    LEUTHER, M
    GJERSET, GF
    COREY, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (24) : 1626 - 1631
  • [6] TRANSIENT HIGH-LEVELS OF VIREMIA IN PATIENTS WITH PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
    DAAR, ES
    MOUDGIL, T
    MEYER, RD
    HO, DD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (14) : 961 - 964
  • [7] IMMUNODEFICIENCY VIRUS TYPE-1 QUANTITATIVE CELL MICROCULTURE AS A MEASURE OF ANTIVIRAL EFFICACY IN A MULTICENTER CLINICAL
    FISCUS, SA
    DEGRUTTOLA, V
    GUPTA, P
    KATZENSTEIN, DA
    MEYER, WA
    LOFARO, ML
    KATZMAN, M
    RAGNI, MV
    REICHELDERFER, PS
    COOMBS, RW
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (02) : 305 - 311
  • [8] FOX R, 1987, AIDS, V1, P35
  • [9] DRUG-THERAPY - CANDIDATE AIDS VACCINES
    GRAHAM, BS
    WRIGHT, PF
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (20) : 1331 - 1339
  • [10] Toward an understanding of the correlates of protective immunity to HIV infection
    Haynes, BF
    Pantaleo, G
    Fauci, AS
    [J]. SCIENCE, 1996, 271 (5247) : 324 - 328